Inventor
BUTORA GABOR
US33 patents
⚠️ This page may combine multiple inventors who share the name “BUTORA GABOR”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MODERNATX INC
15 patentsUS10653712B2May 19, 2020
High purity RNA compositions and methods for preparation thereof
MODERNATX INC73 citations97
US10286086B2May 14, 2019
Alternative nucleic acid molecules and uses thereof
MODERNATX INC78 citations97
US11202793B2Dec 21, 2021
High purity RNA compositions and methods for preparation thereof
MODERNATX INC15 citations93
US12246029B2Mar 11, 2025
High purity RNA compositions and methods for preparation thereof
MODERNATX INC1 citations73
US12233084B2Feb 25, 2025
High purity RNA compositions and methods for preparation thereof
MODERNATX INC1 citations73
US10570388B2Feb 25, 2020
Phosphate replacement MRNA cap analogs
MODERNATX INC3 citations72
US10563195B2Feb 18, 2020
Phosphate replacement mRNA cap analogs
MODERNATX INC4 citations72
US10428106B2Oct 1, 2019
Phosphate replacement mRNA cap analogs
MODERNATX INC4 citations72
US11524023B2Dec 13, 2022
Lipid nanoparticle compositions and methods of formulating the same
MODERNATX INC4 citations67
US12071620B2Aug 27, 2024
Polynucleotides containing a morpholino linker
MODERNATX INC0 citations60
US11434486B2Sep 6, 2022
Polynucleotides containing a morpholino linker
MODERNATX INC1 citations60
US12109274B2Oct 8, 2024
Polynucleotides containing a stabilizing tail region
MODERNATX INC0 citations59
US12508278B2Dec 30, 2025
Lipid nanoparticle compositions and methods of formulating the same
MODERNATX INC0 citations56
US11622972B2Apr 11, 2023
Lipid nanoparticle compositions and methods of formulating the same
MODERNATX INC0 citations56
US11866754B2Jan 9, 2024
Trinucleotide mRNA cap analogs
MODERNATX INC0 citations50
MERCK & CO INC
9 patentsUS7534767B2May 19, 2009
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
MERCK & CO INC69 citations98
US7632821B2Dec 15, 2009
Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
MERCK & CO INC67 citations95
US6812234B2Nov 2, 2004
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
MERCK & CO INC14 citations82
US7247725B2Jul 24, 2007
Gamma-aminoamide modulators of chemokine receptor activity
MERCK & CO INC9 citations74
US6545023B2Apr 8, 2003
Cyclopentyl modulators of chemokine receptor activity
MERCK & CO INC12 citations74
US7390803B2Jun 24, 2008
Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
MERCK & CO INC5 citations62
US7230008B2Jun 12, 2007
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
MERCK & CO INC5 citations61
US7598243B2Oct 6, 2009
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
MERCK & CO INC0 citations41
US7589085B2Sep 15, 2009
Tetrahydropyran heterocyclic cyclopentyl heteroaryl modulators of chemokine receptor activity
MERCK & CO INC0 citations41
MERCK SHARP & DOHME
4 patentsUS9884886B2Feb 6, 2018
Disulfide masked prodrug compositions and methods
MERCK SHARP & DOHME2 citations73
US9732111B2Aug 15, 2017
2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MERCK SHARP & DOHME2 citations71
US7166614B2Jan 23, 2007
Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
MERCK SHARP & DOHME1 citations50
US9624249B2Apr 18, 2017
Nucleoside kinase bypass compositions and methods
MERCK SHARP & DOHME0 citations42